Ciprobay Indications/Uses

Uncomplicated and complicated infections caused by ciprofloxacin susceptible pathogens.
Infections of the respiratory tract: Ciprofloxacin can be regarded as an advisable treatment for pneumonias caused by Klebsiella spp., Enterobacter spp., Proteus spp., Escherichia coli, Pseudomonas aeruginosa, Haemophilus spp., Moraxella catarrhalis, Legionella spp., and staphylococci.
Infections of the middle ear (otitis media), of the paranasal sinuses (sinusitis), especially if these are caused by Gram-negative organisms including Pseudomonas aeruginosa or by staphylococci.
Infections of the eyes.
Infections of the kidneys and/or the efferent urinary tract.
Infections of the genital organs, including adnexitis, gonorrhea, prostatitis.
Infections of the abdominal cavity (e.g. infections of the gastrointestinal tract or of the biliary tract, peritonitis).
Infections of the skin and soft tissue Infections of the bones and joints.
Sepsis.
Infections or imminent risk of infection (prophylaxis) in patients whose immune system has been weakened (e.g. patients on immunosuppressants or have neutropenia).
Selective intestinal decontamination in immunosuppressed patients.
Prophylaxis of invasive infections due to Neisseria meningitidis.
Consideration should be given to available official guidance on the appropriate use of antibacterial agents.
Children: Ciprofloxacin may be used in children for the second- and third-line treatment of complicated urinary tract infections and pyelonephritis due to Escherichia coli (age range applied in clinical studies: 1-17 years) and for the treatment of acute pulmonary exacerbation of cystic fibrosis associated with Pseudomonas aeruginosa (age range applied in clinical studies: 5-17 years).
Treatment should only be initiated after careful benefit/risk evaluation, due to possible adverse events related to joints and/or surrounding tissues.
The clinical trials in children were performed in the indications listed previously. For other indications clinical experience is limited.
Inhalational anthrax (post-exposure) in adults and in children: To reduce the incidence or progression of disease following exposure to aerosolized Bacillus anthracis.